Athersys’ jettisoning of three members of its C-suite has cost it a $100 million financing package. Given an opportunity to cut and run in the wake of the departures, Aspire Capital Fund has terminated the deal and left Athersys looking for a new source of funding.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,